|
|
 |
|
 |
|
|
|
|
Title:
|
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) - IRB #08-08A
|
|
Treatments:
|
Bevacizumab, Cisplatin, Docetaxel, Gemcitabine, Vinorelbine tartrate
|
|
Disease Site:
|
Lung
|
|
Disease SubSite:
|
Non Small Cell Lung
|
|
Drug Provided:
|
Bevacizumab
|
|
Comments:
|
|
|
Eligibility:
|
Diagnosis of stage IB-IIIA (T2-3 N0, T1-3 N1, T1-3 N3) non-small cell lung cancer (NSCLC), Patients with stage IB disease must have tumors measuring equal to or less than 4 cm. Must have undergone complete resection of NSCLC within the past 6-12 weeks. Accepted types of resection include any of the following: Lobectomy , Sleeve lobectomy, Bilobectomy , Pneumonectomy, No resection by segmentectomy or wedge resection. Prior/Concurrent Therapy: See Disease Characteristics, Recovered from prior surgery, No prior systemic chemotherapy, No hormonal cancer therapy or radiotherapy as cancer treatment within the past 5 years, Prior surgery, biologic therapy, hormonal therapy, or radiotherapy for a malignancy diagnosed > 5 years prior to study entry that is now considered cured allowed, No major surgery or open biopsy within the past 28 days, No anticipated major surgery during course of treatment, No core biopsy within the past 7 days, Concurrent therapeutic anticoagulation therapy allowed, No concurrent aminoglycoside antibiotics.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|